<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40"><head><META HTTP-EQUIV="Content-Type" CONTENT="text/html; charset=us-ascii"><meta name=Generator content="Microsoft Word 14 (filtered medium)"><style><!--
/* Font Definitions */
@font-face
{font-family:Wingdings;
panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
{font-family:Wingdings;
panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
{font-family:Tahoma;
panose-1:2 11 6 4 3 5 4 4 2 4;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0in;
margin-bottom:.0001pt;
font-size:11.0pt;
font-family:"Calibri","sans-serif";}
h1
{mso-style-priority:9;
mso-style-link:"Heading 1 Char";
mso-margin-top-alt:auto;
margin-right:0in;
mso-margin-bottom-alt:auto;
margin-left:0in;
font-size:24.0pt;
font-family:"Times New Roman","serif";
font-weight:bold;}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:blue;
text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
{mso-style-priority:99;
color:purple;
text-decoration:underline;}
p
{mso-style-priority:99;
mso-margin-top-alt:auto;
margin-right:0in;
mso-margin-bottom-alt:auto;
margin-left:0in;
font-size:12.0pt;
font-family:"Times New Roman","serif";}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
{mso-style-priority:99;
mso-style-link:"Balloon Text Char";
margin:0in;
margin-bottom:.0001pt;
font-size:8.0pt;
font-family:"Tahoma","sans-serif";}
span.BalloonTextChar
{mso-style-name:"Balloon Text Char";
mso-style-priority:99;
mso-style-link:"Balloon Text";
font-family:"Tahoma","sans-serif";}
span.EmailStyle19
{mso-style-type:personal;
font-family:"Calibri","sans-serif";
color:windowtext;}
span.EmailStyle20
{mso-style-type:personal-reply;
font-family:"Calibri","sans-serif";
color:#1F497D;}
span.Heading1Char
{mso-style-name:"Heading 1 Char";
mso-style-priority:9;
mso-style-link:"Heading 1";
font-weight:bold;}
p.source-org, li.source-org, div.source-org
{mso-style-name:source-org;
mso-margin-top-alt:auto;
margin-right:0in;
mso-margin-bottom-alt:auto;
margin-left:0in;
font-size:12.0pt;
font-family:"Times New Roman","serif";}
p.published, li.published, div.published
{mso-style-name:published;
mso-margin-top-alt:auto;
margin-right:0in;
mso-margin-bottom-alt:auto;
margin-left:0in;
font-size:12.0pt;
font-family:"Times New Roman","serif";}
span.source1
{mso-style-name:source1;}
span.org
{mso-style-name:org;}
.MsoChpDefault
{mso-style-type:export-only;
font-size:10.0pt;}
@page WordSection1
{size:8.5in 11.0in;
margin:1.0in 1.0in 1.0in 1.0in;}
div.WordSection1
{page:WordSection1;}
/* List Definitions */
@list l0
{mso-list-id:1326284395;
mso-list-template-ids:588141754;}
@list l0:level1
{mso-level-number-format:bullet;
mso-level-text:\F0B7;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l0:level3
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level4
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level5
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level6
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level7
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level8
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level9
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
ol
{margin-bottom:0in;}
ul
{margin-bottom:0in;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]--></head><body lang=EN-US link=blue vlink=purple><div class=WordSection1><p class=MsoNormal><span style='color:#1F497D'>Oy vey, this is a bad day for those with a family member suffering from AD:<o:p></o:p></span></p><p class=MsoNormal><span style='color:#1F497D'><o:p> </o:p></span></p><p class=MsoNormal><span style='color:#1F497D'><a href="http://www.foxnews.com/health/2012/08/08/popcorn-ingredient-found-to-be-linked-with-alzheimer/?test=latestnews">http://www.foxnews.com/health/2012/08/08/popcorn-ingredient-found-to-be-linked-with-alzheimer/?test=latestnews</a><o:p></o:p></span></p><p class=MsoNormal><span style='color:#1F497D'><o:p> </o:p></span></p><p class=MsoNormal><span style='color:#1F497D'><o:p> </o:p></span></p><h1 style='background:white'><span lang=EN style='font-family:"Arial","sans-serif";color:black'>Popcorn ingredient found to be linked with Alzheimer's<o:p></o:p></span></h1><p class=published style='background:white'><span lang=EN style='font-size:9.0pt;font-family:"Arial","sans-serif";color:black'>Published August 08, 2012<o:p></o:p></span></p><p class=source-org style='background:white'><span class=org><span lang=EN style='font-size:9.0pt;font-family:"Arial","sans-serif";color:black'>FoxNews.com</span></span><span lang=EN style='font-size:9.0pt;font-family:"Arial","sans-serif";color:black'><o:p></o:p></span></p><p style='background:white'><span lang=EN style='font-size:9.0pt;font-family:"Arial","sans-serif";color:black'>Movie popcorn has often been criticized for its high calorie count, but now the tasty treat may harm more than just your waistline.<o:p></o:p></span></p><p style='background:white'><span lang=EN style='font-size:9.0pt;font-family:"Arial","sans-serif";color:black'>A recent study has found that diacetyl, an ingredient in popcorn responsible for its buttery flavor and smell, may be linked to Alzheimer’s disease, UPI.com reported…<o:p></o:p></span></p><p class=MsoNormal style='background:white'><span lang=EN style='font-size:9.0pt;font-family:"Arial","sans-serif";color:black'><br><br>Read more: <a href="http://www.foxnews.com/health/2012/08/08/popcorn-ingredient-found-to-be-linked-with-alzheimer/?test=latestnews#ixzz22zyRsUL2"><span style='color:#003399'>http://www.foxnews.com/health/2012/08/08/popcorn-ingredient-found-to-be-linked-with-alzheimer/?test=latestnews#ixzz22zyRsUL2</span></a><o:p></o:p></span></p><p class=MsoNormal><span style='color:#1F497D'><o:p> </o:p></span></p><p class=MsoNormal><span style='color:#1F497D'><o:p> </o:p></span></p><p class=MsoNormal><span style='color:#1F497D'><o:p> </o:p></span></p><p class=MsoNormal><span style='color:#1F497D'><o:p> </o:p></span></p><div><div style='border:none;border-top:solid #B5C4DF 1.0pt;padding:3.0pt 0in 0in 0in'><p class=MsoNormal><b><span style='font-size:10.0pt;font-family:"Tahoma","sans-serif"'>From:</span></b><span style='font-size:10.0pt;font-family:"Tahoma","sans-serif"'> spike [mailto:spike66@att.net] <br><b>Sent:</b> Wednesday, August 08, 2012 3:49 PM<br><b>To:</b> 'ExI chat list'<br><b>Subject:</b> bexarotene papers<o:p></o:p></span></p></div></div><p class=MsoNormal><o:p> </o:p></p><p class=MsoNormal><o:p> </o:p></p><p class=MsoNormal>Apparently bexarotene is a bust:<o:p></o:p></p><p class=MsoNormal><o:p> </o:p></p><p class=MsoNormal><a href="http://vitals.nbcnews.com/_news/2012/08/08/13166642-alzheimers-treatment-not-the-hoped-for-miracle?lite">http://vitals.nbcnews.com/_news/2012/08/08/13166642-alzheimers-treatment-not-the-hoped-for-miracle?lite</a><o:p></o:p></p><p class=MsoNormal><o:p> </o:p></p><p class=MsoNormal>Damn.<o:p></o:p></p><p class=MsoNormal><o:p> </o:p></p><p class=MsoNormal>spike<o:p></o:p></p><p class=MsoNormal><o:p> </o:p></p><p class=MsoNormal style='mso-margin-top-alt:12.0pt;margin-right:0in;margin-bottom:12.0pt;margin-left:0in'><b><span lang=EN style='font-size:10.5pt;font-family:"Arial","sans-serif";color:#354D7D'>Alzheimer's treatment not the hoped for miracle<o:p></o:p></span></b></p><p class=MsoNormal><span lang=EN style='font-size:7.5pt;font-family:"Arial","sans-serif";color:#333333'>By Robert Bazell, Chief science and medical correspondent, NBC News<o:p></o:p></span></p><p class=MsoNormal><span lang=EN style='font-size:7.5pt;font-family:"Arial","sans-serif";color:#333333'><o:p> </o:p></span></p><p class=MsoNormal style='mso-margin-top-alt:auto'><span lang=EN style='font-size:7.5pt;font-family:"Arial","sans-serif";color:#333333'>Robert Bazell, NBC News<o:p></o:p></span></p><p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto'><span lang=EN style='font-size:7.5pt;font-family:"Arial","sans-serif";color:#333333'>A cancer drug is turning out not to be the miraculous treatment for Alzheimer’s that many had hoped. Two papers out Wednesday in the New England Journal of Medicine warn families of Alzheimer’s victims not to seek treatment with Targretin (generic name: bexarotene). <o:p></o:p></span></p><p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto'><span lang=EN style='font-size:7.5pt;font-family:"Arial","sans-serif";color:#333333'>Last February a study from Case Western Reserve University reported that the drug rapidly cleared the clumps of protein known as beta-amyloid, the hallmark of Alzheimer’s, from the brains of mice with a version of the disease. Since the drug was already on the market, approved as a treatment for lymphoma, doctors could immediately prescribe it in so-called off-label use for Alzheimer’s. And thousands of families understandably asked.<o:p></o:p></span></p><p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto'><span lang=EN style='font-size:7.5pt;font-family:"Arial","sans-serif";color:#333333'>But one mouse study does not prove that a drug is effective in humans. The drug is expensive – about $14,000 a year - and off-label use is often not covered by insurance. The drug can also bring on severe side-effects. In one paper in the Journal, Justin Lowenthal, Sara Hull and Steven Pearson of the National Institutes of Health and Massachusetts General Hospital conclude that for this drug “even if the patients are willing to take the risks for the potential benefit, the physician's answer should be no.” In the second paper Frank LaFerla of the University of California, Irvine observes “the field has been down this road before, as successes in preclinical models have thus far not translated well into the clinic.”<o:p></o:p></span></p><p class=MsoNormal><o:p> </o:p></p></div></body></html>